<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Serotonin modulators: Pharmacology, administration, and side effects
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Serotonin modulators: Pharmacology, administration, and side effects
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Serotonin modulators: Pharmacology, administration, and side effects
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Michael Hirsch, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Robert J Birnbaum, MD, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Peter P Roy-Byrne, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            David Solomon, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Mar 21, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H665875">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Advances in understanding brain neurophysiology have led to the development of serotonin modulators, including [
         <a href="#rid1">
          1
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9684" href="/z/d/drug information/9684.html" rel="external">
          Nefazodone
         </a>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="10013" href="/z/d/drug information/10013.html" rel="external">
          Trazodone
         </a>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="16102" href="/z/d/drug information/16102.html" rel="external">
          Vilazodone
         </a>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="91014" href="/z/d/drug information/91014.html" rel="external">
          Vortioxetine
         </a>
        </p>
        <p>
        </p>
        <p>
         The serotonin modulators are distinct from other classes of antidepressants that include selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, atypical antidepressants, tricyclics, and monoamine oxidase inhibitors. Serotonin modulators act as antagonists and agonists at postsynaptic serotonin receptors and inhibit reuptake of postsynaptic serotonin to varying degrees; effects upon norepinephrine reuptake are minimal.
        </p>
        <p>
         The pharmacology, administration, and side effects of serotonin modulators are reviewed here. Choosing a regimen for the initial treatment of depression and treatment of resistant depression is discussed separately, as are other antidepressant drug classes:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/1725.html" rel="external">
          "Unipolar major depression in adults: Choosing initial treatment"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/14685.html" rel="external">
          "Unipolar depression in adults: Choosing treatment for resistant depression"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/14675.html" rel="external">
          "Selective serotonin reuptake inhibitors: Pharmacology, administration, and side effects"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/1713.html" rel="external">
          "Serotonin-norepinephrine reuptake inhibitors: Pharmacology, administration, and side effects"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/85816.html" rel="external">
          "Atypical antidepressants: Pharmacology, administration, and side effects"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/1717.html" rel="external">
          "Tricyclic and tetracyclic drugs: Pharmacology, administration, and side effects"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/1715.html" rel="external">
          "Monoamine oxidase inhibitors (MAOIs): Pharmacology, administration, safety, and side effects"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph utd-adt-cnt utd-adt-pathwys">
          ●
         </span>
         <span class="utd-adt-cnt utd-adt-pathwys utd-content-138287">
          (Related Pathway(s):
          <a class="utd-content-138287" href="/pathway/138287?topicRef=86265&amp;source=see_link">
           Unipolar major depression: Initial pharmacologic therapy in adults
          </a>
          .)
         </span>
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H666429">
         <span class="h1">
          GENERAL PRINCIPLES
         </span>
        </p>
        <p class="headingAnchor" id="H28673015">
         <span class="h2">
          Drug interactions and metabolism
         </span>
         <span class="headingEndMark">
          —
         </span>
         Coadministration of serotonin modulators with another drug can decrease or increase the metabolism of the serotonin modulator, which may necessitate either adjusting the dose of the serotonin modulator or using a different antidepressant. Thus, prior to initiating or altering therapy with serotonin modulators, clinicians should check interactions with other medications using the
         <a class="external" href="/drug-interactions">
          drug interactions program
         </a>
         included in UpToDate. The
         <a class="external" href="/drug-interactions">
          drug interaction tool
         </a>
         provides specific dose recommendations for prescribing serotonin modulators concomitantly with drugs that affect the serotonin modulator’s metabolism.
        </p>
        <p>
         Serotonin modulators are metabolized by hepatic cytochrome P450 3A4 (CYP3A4) or 2D6 (CYP2D6) enzymes. Administering a serotonin modulator in conjunction with another drug that inhibits these enzymes can increase serum concentrations of the serotonin modulator, resulting in drug accumulation and toxicity. Prescribing a serotonin modulator concurrently with medications that induce the enzymes can decrease serum concentrations of the serotonin modulator and lead to therapeutic failure. The hepatic metabolism of the serotonin modulators includes the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Trazodone
         </strong>
         <strong>
          and
         </strong>
         <strong>
          vilazodone
         </strong>
         –
         <a class="drug drug_general" data-topicid="10013" href="/z/d/drug information/10013.html" rel="external">
          Trazodone
         </a>
         and
         <a class="drug drug_general" data-topicid="16102" href="/z/d/drug information/16102.html" rel="external">
          vilazodone
         </a>
         undergo extensive hepatic metabolism by CYP3A4 [
         <a href="#rid2">
          2,3
         </a>
         ]. Strong CYP3A4 inhibitors and inducers are listed in the table  (
         <a class="graphic graphic_table graphicRef76992" href="/z/d/graphic/76992.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Vortioxetine
         </strong>
         –
         <a class="drug drug_general" data-topicid="91014" href="/z/d/drug information/91014.html" rel="external">
          Vortioxetine
         </a>
         undergoes extensive metabolism by CYP2D6 and is also metabolized by other CYP enzymes [
         <a href="#rid4">
          4
         </a>
         ]. Drug-drug interactions can occur when vortioxetine is coadministered with medications that inhibit CYP2D6 metabolism, or medications that induce other CYP metabolic pathways. CYP2D6 inhibitors are listed in the table  (
         <a class="graphic graphic_table graphicRef116164" href="/z/d/graphic/116164.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Nefazodone
         </strong>
         – Although
         <a class="drug drug_general" data-topicid="9684" href="/z/d/drug information/9684.html" rel="external">
          nefazodone
         </a>
         seems to undergo extensive metabolism by CYP3A4 based upon in vitro data, this has not been well studied [
         <a href="#rid5">
          5,6
         </a>
         ]. Strong CYP3A4 inhibitors and inducers are listed in the table  (
         <a class="graphic graphic_table graphicRef76992" href="/z/d/graphic/76992.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_general" data-topicid="9684" href="/z/d/drug information/9684.html" rel="external">
          Nefazodone
         </a>
         is itself a strong inhibitor of CYP3A4 and can elevate levels of comedications that are dependent upon CYP3A4 for clearance.
        </p>
        <p>
        </p>
        <p>
         Serotonin modulators can also interact with other medications that elevate serotonin in the central nervous system, potentially resulting in the serotonin syndrome. These drug-drug interactions (eg, with monoamine oxidase inhibitors) can be severe and are described in more detail separately. (See
         <a class="medical medical_review" href="/z/d/html/301.html" rel="external">
          "Serotonin syndrome (serotonin toxicity)"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H666436">
         <span class="h2">
          Guidelines to review with patients
         </span>
         <span class="headingEndMark">
          —
         </span>
         Prior to prescribing serotonin modulators, clinicians should discuss:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Drug interactions
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Side effects
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Time to response
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Stopping the medication
        </p>
        <p>
        </p>
        <p>
         Common and serious side effects  (
         <a class="graphic graphic_table graphicRef62488" href="/z/d/graphic/62488.html" rel="external">
          table 3
         </a>
         ) and the need to take the medication as prescribed rather than on an as needed basis should be reviewed. Patients should also be informed that although some response often occurs within the first two weeks of treatment, it may take many weeks (eg, 8 to 14) for a full response (severity of illness and comorbid disease may affect how quickly depressed patients respond to treatment) [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H666443">
         <span class="h2">
          Medical tests and plasma levels
         </span>
         <span class="headingEndMark">
          —
         </span>
         No specific medical tests are required before starting serotonin modulators, and drug serum concentrations are not routinely monitored because they have not been shown to correlate with clinical response. However, levels can assess adherence and whether unresponsive patients are rapid metabolizers. Levels can also establish that it is safe to begin another serotonergic drug (eg, a monoamine oxidase inhibitor) after discontinuing a serotonin modulator, in order to avoid the serotonin syndrome  (
         <a class="graphic graphic_table graphicRef64604" href="/z/d/graphic/64604.html" rel="external">
          table 4
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/301.html" rel="external">
          "Serotonin syndrome (serotonin toxicity)"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H666450">
         <span class="h2">
          Dosing
         </span>
         <span class="headingEndMark">
          —
         </span>
         We suggest starting with a low dose in order to avoid side effects and slowly increasing the dose. Starting doses and target dose ranges of each serotonin modulator are listed in the table  (
         <a class="graphic graphic_table graphicRef53818" href="/z/d/graphic/53818.html" rel="external">
          table 5
         </a>
         ). Depressed patients with high levels of anxiety may tolerate the medication better by starting with half of the suggested dose. Doses are adjusted according to patient response, tolerability, and clinical urgency.
        </p>
        <p>
         Finding the effective dose of an antidepressant involves trial and error. After starting the drug and titrating up to the minimum effective dose, response should be monitored over the following two to four weeks. For patients who tolerate the antidepressant but do not respond, we continue titrating up the dose slowly (to avoid side effects) every two to four weeks. For unresponsive patients who do not tolerate the drug, we suggest switching to a different antidepressant. (See
         <a class="medical medical_review" href="/z/d/html/1716.html" rel="external">
          "Switching antidepressant medications in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1725.html" rel="external">
          "Unipolar major depression in adults: Choosing initial treatment"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/14685.html" rel="external">
          "Unipolar depression in adults: Choosing treatment for resistant depression", section on 'Next step treatment'
         </a>
         .)
        </p>
        <p>
         Patients who recover from an episode of major depression should generally receive maintenance treatment with the full dose that successfully resolved the episode, rather than a lower dose. (See
         <a class="medical medical_review" href="/z/d/html/14674.html" rel="external">
          "Unipolar depression in adults: Continuation and maintenance treatment", section on 'Dose'
         </a>
         .)
        </p>
        <p>
         Separate sections below discuss specific dose recommendations for each serotonin modulator.
        </p>
        <p class="headingAnchor" id="H666457">
         <span class="h2">
          Pregnancy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Treatment of pregnant women with antidepressants is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1703.html" rel="external">
          "Severe antenatal unipolar major depression: Choosing treatment"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H667313">
         <span class="h2">
          Serotonin syndrome
         </span>
         <span class="headingEndMark">
          —
         </span>
         Serotonin modulators increase serotonergic neurotransmission and can cause the serotonin syndrome. (See
         <a class="medical medical_review" href="/z/d/html/301.html" rel="external">
          "Serotonin syndrome (serotonin toxicity)"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3491829">
         <span class="h2">
          Suicide
         </span>
         <span class="headingEndMark">
          —
         </span>
         The potential effect of antidepressants on suicidal ideation and behavior in adults is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/14672.html" rel="external">
          "Effect of antidepressants on suicide risk in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H664422">
         <span class="h1">
          NEFAZODONE
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9684" href="/z/d/drug information/9684.html" rel="external">
          Nefazodone
         </a>
         is used to treat major depression and premenstrual syndrome. The drug is contraindicated in patients with elevated serum transaminases, active liver disease, or liver injury due to previous nefazodone treatment.
        </p>
        <p class="headingAnchor" id="H664429">
         <span class="h2">
          Pharmacology
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9684" href="/z/d/drug information/9684.html" rel="external">
          Nefazodone
         </a>
         is a phenylpiperazine whose structure resembles that of
         <a class="drug drug_general" data-topicid="10013" href="/z/d/drug information/10013.html" rel="external">
          trazodone
         </a>
         [
         <a href="#rid1">
          1,8
         </a>
         ]. Nefazodone antagonizes and down regulates postsynaptic serotonin 5-HT2A receptors, and weakly inhibits presynaptic serotonin and norepinephrine reuptake; these actions increase activity at the serotonin 5-HT1A receptors [
         <a href="#rid1">
          1,9,10
         </a>
         ]. The drug has little to no affinity for alpha-adrenergic receptors, cholinergic, dopamine D2, and histamine H1 receptors. The pharmacokinetic parameters of nefazodone are displayed in the table  (
         <a class="graphic graphic_table graphicRef88062" href="/z/d/graphic/88062.html" rel="external">
          table 6
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H664436">
         <span class="h2">
          Administration, dose, and discontinuation
         </span>
         <span class="headingEndMark">
          —
         </span>
         The usual starting dose of
         <a class="drug drug_general" data-topicid="9684" href="/z/d/drug information/9684.html" rel="external">
          nefazodone
         </a>
         for major depression is 100 mg twice daily  (
         <a class="graphic graphic_table graphicRef53818" href="/z/d/graphic/53818.html" rel="external">
          table 5
         </a>
         ) [
         <a href="#rid9">
          9
         </a>
         ]. For patients who do not respond after two to four weeks, the dose is increased to 150 to 200 mg twice daily. The dose is increased further by increments of 100 to 200 mg per day every two to four weeks until the desired clinical response is achieved; the maximum dose is 300 mg twice daily. In clinically urgent situations, dose increases can occur once a week as tolerated. The effectiveness and tolerability of once daily and twice daily dosing may be comparable [
         <a href="#rid11">
          11
         </a>
         ].
        </p>
        <p>
         Based upon in vitro data,
         <a class="drug drug_general" data-topicid="9684" href="/z/d/drug information/9684.html" rel="external">
          nefazodone
         </a>
         seems to undergo extensive metabolism by cytochrome P450 3A4 (CYP3A4) enzymes. However, this has not been well studied and the manufacturer does not provide dose adjustment recommendations for use with CYP3A4 inhibitors or inducers [
         <a href="#rid5">
          5,6
         </a>
         ]. Nevertheless, if nefazodone is co-prescribed with a strong inhibitor of CYP3A4, decreasing the dose of nefazodone may be warranted; if nefazodone is given concomitantly with a strong inducer, the dose of nefazodone may need to be increased. Strong CYP3A4 inhibitors and inducers are listed in the table  (
         <a class="graphic graphic_table graphicRef76992" href="/z/d/graphic/76992.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p>
         Although abrupt discontinuation of
         <a class="drug drug_general" data-topicid="9684" href="/z/d/drug information/9684.html" rel="external">
          nefazodone
         </a>
         does not cause a withdrawal syndrome, we taper the drug over one week before stopping it, which is consistent with the preferred method of discontinuing any psychotropic medication. In two randomized trials, patients with major depression (n = 259 and 131) who received nefazodone for 16 weeks were randomly assigned to either continue the drug or abruptly stop it and start placebo (as part of relapse prevention studies); the incidence of discontinuation symptoms was comparable for the two groups [
         <a href="#rid12">
          12,13
         </a>
         ]. Additional information about discontinuing antidepressants is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/105323.html" rel="external">
          "Discontinuing antidepressant medications in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H664443">
         <span class="h2">
          Side effects
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9684" href="/z/d/drug information/9684.html" rel="external">
          Nefazodone
         </a>
         can injure the liver; the estimated incidence of hepatotoxicity based upon a national registry in Spain is 29 cases per 100,000 patients per year [
         <a href="#rid14">
          14
         </a>
         ]. Adverse hepatic reactions can occur with doses as low as 100 mg per day and generally occur within six months of starting the drug [
         <a href="#rid15">
          15
         </a>
         ]. These reactions include acute liver failure; the estimated incidence is 1 case per 200,000 to 300,000 patient years, which is three to four times greater than expected [
         <a href="#rid16">
          16
         </a>
         ]. A 2010 study of the World Health Organization Programme for International Drug Monitoring database found 94 cases of acute liver failure attributed to nefazodone, including patients who received a liver transplant or died [
         <a href="#rid17">
          17
         </a>
         ]. Thus, nefazodone is not commonly used in United States; generic versions are available, but the brand-name version is no longer manufactured. In addition, the drug has been withdrawn from the market in several countries. Patients receiving the drug should be monitored for signs and symptoms of liver failure (nausea, abdominal pain, jaundice, impaired synthetic function, coagulopathy, and delirium). Although periodic liver function tests (eg, every two to six months) may possibly be useful, there is no evidence that testing prevents hepatic injury [
         <a href="#rid12">
          12
         </a>
         ].
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9684" href="/z/d/drug information/9684.html" rel="external">
          Nefazodone
         </a>
         can cause several other side effects  (
         <a class="graphic graphic_table graphicRef62488" href="/z/d/graphic/62488.html" rel="external">
          table 3
         </a>
         ). A pooled analysis of randomized trials (n = 2185 patients, most with unipolar major depression) found that the incidence of discontinuing nefazodone because of side effects was 12 percent and for placebo was 7 percent [
         <a href="#rid18">
          18
         </a>
         ]. Adverse effects that occurred more frequently with nefazodone included:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Nausea – 21 percent of patients who received
         <a class="drug drug_general" data-topicid="9684" href="/z/d/drug information/9684.html" rel="external">
          nefazodone
         </a>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Somnolence – 19 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Dry mouth – 19 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Dizziness – 12 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Constipation – 11 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Weakness – 11 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Blurred vision – 6 percent
        </p>
        <p>
        </p>
        <p>
         Each of these adverse effects, except dry mouth and weakness, appear to be dose related and less likely to occur at doses ≤300 mg per day [
         <a href="#rid9">
          9
         </a>
         ].
        </p>
        <p>
         Reduced systolic blood pressure (≤90 mmHg and ≥20 mmHg reduction from baseline) occurred in more patients who received
         <a class="drug drug_general" data-topicid="9684" href="/z/d/drug information/9684.html" rel="external">
          nefazodone
         </a>
         than placebo (5 versus 3 percent), but the incidence of syncope was comparable (0.02 and 0.03 percent) [
         <a href="#rid18">
          18
         </a>
         ]. In addition, asymptomatic sinus bradycardia was detected by electrocardiogram in more patients who received nefazodone than placebo (1.3 versus 0.4 percent).
        </p>
        <p>
         Sexual dysfunction with
         <a class="drug drug_general" data-topicid="9684" href="/z/d/drug information/9684.html" rel="external">
          nefazodone
         </a>
         and placebo appear to be comparable, based upon a meta-analysis [
         <a href="#rid19">
          19
         </a>
         ] as well as a pooled analysis of randomized trials (n = 2185 patients) [
         <a href="#rid18">
          18
         </a>
         ]. In addition, weight gain during treatment lasting between 3 to 13 months is comparable for nefazodone and placebo [
         <a href="#rid18">
          18
         </a>
         ].
        </p>
        <p>
         Compared with selective serotonin reuptake inhibitors,
         <a class="drug drug_general" data-topicid="9684" href="/z/d/drug information/9684.html" rel="external">
          nefazodone
         </a>
         is less activating and causes less gastrointestinal distress (eg, nausea, diarrhea, and anorexia), sexual dysfunction, and weight gain during long-term treatment (eg, 16 to 46 weeks), but causes more dry mouth, dizziness, constipation, visual disturbances, and confusion [
         <a href="#rid9">
          9,20
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H664450">
         <span class="h2">
          Overdose
         </span>
         <span class="headingEndMark">
          —
         </span>
         The clinical features, toxicology, and management of overdoses with
         <a class="drug drug_general" data-topicid="16102" href="/z/d/drug information/16102.html" rel="external">
          vilazodone
         </a>
         are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/15239.html" rel="external">
          "Acute poisoning from atypical (non-SSRI) antidepressants, including serotonin modulators and serotonin-norepinephrine reuptake inhibitors (SNRIs)"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H664457">
         <span class="h1">
          TRAZODONE
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="10013" href="/z/d/drug information/10013.html" rel="external">
          Trazodone
         </a>
         is used to treat major depression as well as functional dyspepsia. In addition, it is often used as a hypnotic to treat insomnia in the context of depression, as well as insomnia associated with antidepressants (eg,
         <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">
          bupropion
         </a>
         or
         <a class="drug drug_general" data-topicid="8465" href="/z/d/drug information/8465.html" rel="external">
          fluoxetine
         </a>
         ) [
         <a href="#rid21">
          21
         </a>
         ]. However, the efficacy of trazodone for insomnia in the absence of depression appears to be short-lived. (See
         <a class="medical medical_review" href="/z/d/html/97868.html" rel="external">
          "Pharmacotherapy for insomnia in adults", section on 'Trazodone'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H664464">
         <span class="h2">
          Pharmacology
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="10013" href="/z/d/drug information/10013.html" rel="external">
          Trazodone
         </a>
         is a triazolopyridine whose structure resembles that of
         <a class="drug drug_general" data-topicid="9684" href="/z/d/drug information/9684.html" rel="external">
          nefazodone
         </a>
         [
         <a href="#rid8">
          8
         </a>
         ]. Trazodone acts upon postsynaptic serotonin 5-HT2A and 5-HT2C receptors and weakly inhibits presynaptic serotonin reuptake. The effects appear to be dose dependent such that at low doses the drug acts as a serotonin antagonist and at high doses as a serotonin agonist [
         <a href="#rid8">
          8,22
         </a>
         ]. Effects on norepinephrine and dopamine reuptake are minimal. In addition, the drug blocks postsynaptic alpha-adrenergic receptors (which may account for the side effects of orthostatic hypotension and priapism) and histamine H1 receptors (which may explain its sedative effect) [
         <a href="#rid8">
          8,22,23
         </a>
         ]. The drug does not affect cholinergic receptors.
        </p>
        <p>
         The pharmacokinetic parameters of
         <a class="drug drug_general" data-topicid="10013" href="/z/d/drug information/10013.html" rel="external">
          trazodone
         </a>
         are displayed in the table  (
         <a class="graphic graphic_table graphicRef88062" href="/z/d/graphic/88062.html" rel="external">
          table 6
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H664471">
         <span class="h2">
          Administration, dose, and discontinuation
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="10013" href="/z/d/drug information/10013.html" rel="external">
          Trazodone
         </a>
         immediate release is typically dosed as follows for major depression  (
         <a class="graphic graphic_table graphicRef53818" href="/z/d/graphic/53818.html" rel="external">
          table 5
         </a>
         ). The drug is started at 50 mg twice daily, which is then increased by increments of 50 mg per day every three to seven days to a dose of 75 to 150 mg twice daily. The dose is subsequently increased by 50 to 100 mg per day every two to four weeks until the desired clinical response is achieved, to a maximum dose of 600 mg per day. Doses &gt;400 mg per day warrant cautious use and additional monitoring, particularly in the elderly and other patients at risk for cardiovascular toxicity. The drug’s sedative effects may be better tolerated if patients are given a smaller daytime dose and larger bedtime dose (eg, 100 mg in the morning and 200 mg at bedtime); some patients receive the entire dose at bedtime. An extended release preparation is available in a few countries, but no longer in the United States.
        </p>
        <p>
         Patients with insomnia associated with antidepressants (eg, selective serotonin reuptake inhibitors) may benefit from immediate release
         <a class="drug drug_general" data-topicid="10013" href="/z/d/drug information/10013.html" rel="external">
          trazodone
         </a>
         50 to 100 mg at bedtime [
         <a href="#rid21">
          21
         </a>
         ]. When adjunctive trazodone is prescribed as a hypnotic for insomnia associated with depression, doses typically range from 50 to 300 mg at bedtime [
         <a href="#rid24">
          24
         </a>
         ]. Although doses up to 600 mg at bedtime have been studied for insomnia in the context of depression, we rarely use more than 200 mg.
        </p>
        <p>
         <a class="drug drug_general" data-topicid="10013" href="/z/d/drug information/10013.html" rel="external">
          Trazodone
         </a>
         undergoes extensive hepatic metabolism by hepatic cytochrome P450 3A4 (CYP3A4) enzymes [
         <a href="#rid3">
          3
         </a>
         ]. If trazodone is co-prescribed with a strong inhibitor of CYP3A4, decreasing the dose of trazodone may be warranted. If trazodone is given concomitantly with a strong inducer, the dose of trazodone may need to be increased. Strong CYP3A4 inhibitors and inducers are listed in the table  (
         <a class="graphic graphic_table graphicRef76992" href="/z/d/graphic/76992.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p>
         We suggest tapering the drug over two to four weeks prior to discontinuation. Rapid or abrupt discontinuation of
         <a class="drug drug_general" data-topicid="10013" href="/z/d/drug information/10013.html" rel="external">
          trazodone
         </a>
         may be followed by withdrawal symptoms, including gastrointestinal distress, anxiety, and sleep disturbances [
         <a href="#rid25">
          25
         </a>
         ]. Additional information about discontinuing antidepressants is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/105323.html" rel="external">
          "Discontinuing antidepressant medications in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H664478">
         <span class="h2">
          Side effects
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="10013" href="/z/d/drug information/10013.html" rel="external">
          Trazodone
         </a>
         can cause several side effects  (
         <a class="graphic graphic_table graphicRef62488" href="/z/d/graphic/62488.html" rel="external">
          table 3
         </a>
         ) [
         <a href="#rid24">
          24,25
         </a>
         ]. A randomized trial that compared trazodone immediate release with placebo in 153 patients with major depression found that discontinuation of treatment due to side effects was greater in patients who received trazodone than placebo (23 versus 4 percent); trazodone caused a higher incidence of [
         <a href="#rid26">
          26
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Sedation – 61 percent of patients who received
         <a class="drug drug_general" data-topicid="10013" href="/z/d/drug information/10013.html" rel="external">
          trazodone
         </a>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Dizziness – 36 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Dry mouth – 27 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Nausea – 19 percent
        </p>
        <p>
        </p>
        <p>
         Orthostatic hypotension and headache are also common with
         <a class="drug drug_general" data-topicid="10013" href="/z/d/drug information/10013.html" rel="external">
          trazodone
         </a>
         [
         <a href="#rid27">
          27
         </a>
         ].
        </p>
        <p>
         Rare but serious side effects of
         <a class="drug drug_general" data-topicid="10013" href="/z/d/drug information/10013.html" rel="external">
          trazodone
         </a>
         include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Priapism – Penile priapism secondary to
         <a class="drug drug_general" data-topicid="10013" href="/z/d/drug information/10013.html" rel="external">
          trazodone
         </a>
         is an emergency that should be evaluated immediately by a urologist (rare cases of clitoral priapism have also been reported) [
         <a href="#rid28">
          28
         </a>
         ]. Trazodone induced priapism is estimated to occur 1 in 1000 to 1 in 10,000 patients, and has been reported at doses ranging from 50 to 400 mg per day. Although most cases occur within the first month of treatment, priapism may occur up to 18 months after onset of treatment. A prolonged erection during treatment may be a risk factor for subsequent priapism. Additional information about priapism is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/6887.html" rel="external">
          "Priapism"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cardiac arrhythmias – A review identified case reports of atrial and ventricular arrhythmias in patients treated with
         <a class="drug drug_general" data-topicid="10013" href="/z/d/drug information/10013.html" rel="external">
          trazodone
         </a>
         [
         <a href="#rid25">
          25
         </a>
         ]. Thus, the drug should be used with caution in patients with cardiac disease.
        </p>
        <p>
        </p>
        <p>
         <a class="drug drug_general" data-topicid="10013" href="/z/d/drug information/10013.html" rel="external">
          Trazodone
         </a>
         appears to be weight neutral during treatment lasting 4 to 12 weeks, based upon a meta-analysis of three heterogeneous randomized trials (n = 155 patients treated with trazodone for with major depression) [
         <a href="#rid29">
          29
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H664485">
         <span class="h2">
          Overdose
         </span>
         <span class="headingEndMark">
          —
         </span>
         The clinical features, toxicology, and management of overdoses with
         <a class="drug drug_general" data-topicid="16102" href="/z/d/drug information/16102.html" rel="external">
          vilazodone
         </a>
         are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/15239.html" rel="external">
          "Acute poisoning from atypical (non-SSRI) antidepressants, including serotonin modulators and serotonin-norepinephrine reuptake inhibitors (SNRIs)"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H664492">
         <span class="h1">
          VILAZODONE
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="16102" href="/z/d/drug information/16102.html" rel="external">
          Vilazodone
         </a>
         is used to treat major depression.
        </p>
        <p class="headingAnchor" id="H664499">
         <span class="h2">
          Pharmacology
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="16102" href="/z/d/drug information/16102.html" rel="external">
          Vilazodone
         </a>
         is an indolalkylamine that inhibits presynaptic reuptake of serotonin and also acts as a partial agonist at postsynaptic serotonin 5-HT1A receptors [
         <a href="#rid30">
          30
         </a>
         ]. Inhibition of norepinephrine and dopamine reuptake is minimal. The pharmacokinetic parameters of vilazodone are displayed in the table  (
         <a class="graphic graphic_table graphicRef88062" href="/z/d/graphic/88062.html" rel="external">
          table 6
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H664506">
         <span class="h2">
          Administration, dose, and discontinuation
         </span>
         <span class="headingEndMark">
          —
         </span>
         The usual starting dose of
         <a class="drug drug_general" data-topicid="16102" href="/z/d/drug information/16102.html" rel="external">
          vilazodone
         </a>
         for major depression is 10 mg per day at bedtime, for one week  (
         <a class="graphic graphic_table graphicRef53818" href="/z/d/graphic/53818.html" rel="external">
          table 5
         </a>
         ). The dose is then increased to 20 mg per day for week 2 [
         <a href="#rid31">
          31
         </a>
         ]. This two-week titration schedule is intended to reduce gastrointestinal toxicity. The target dose is 20 to 40 mg per day. The drug should be taken with food to increase bioavailability. Dose adjustments are not required for patients with severe renal impairment [
         <a href="#rid30">
          30
         </a>
         ]; use of the drug in patients with severe hepatic impairment has not been studied [
         <a href="#rid32">
          32
         </a>
         ].
        </p>
        <p>
         Concurrent use of
         <a class="drug drug_general" data-topicid="16102" href="/z/d/drug information/16102.html" rel="external">
          vilazodone
         </a>
         with other medications that inhibit or induce hepatic cytochrome P450 3A4 (CYP3A4) metabolism can alter vilazodone serum concentrations, which may necessitate adjusting the dose of vilazodone. Strong CYP3A4 inhibitors and inducers are listed in the table  (
         <a class="graphic graphic_table graphicRef76992" href="/z/d/graphic/76992.html" rel="external">
          table 1
         </a>
         ). Recommendations for specific vilazodone dose adjustments are as follows [
         <a href="#rid2">
          2
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="16102" href="/z/d/drug information/16102.html" rel="external">
          Vilazodone
         </a>
         given with strong CYP3A4 inhibitors – Vilazodone dose should not exceed 20 mg once daily. If the CYP3A4 inhibitor is discontinued, readjust vilazodone to original dose.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="16102" href="/z/d/drug information/16102.html" rel="external">
          Vilazodone
         </a>
         given with strong CYP3A4 inducers – Based upon clinical response, clinicians may need to increase the vilazodone dose two-fold when coadministered with CYP3A4 inducer for more than 14 days. Maximum daily dose of vilazodone is 80 mg. If the CYP3A4 inducer is discontinued, reduce vilazodone dose to the original dose over 7 to 14 days.
        </p>
        <p>
        </p>
        <p>
         Specific interactions of serotonin modulators with other medications can be determined using the
         <a class="external" href="/drug-interactions">
          drug interactions program
         </a>
         included in UpToDate.
        </p>
        <p>
         Although withdrawal symptoms due to abrupt discontinuation of
         <a class="drug drug_general" data-topicid="16102" href="/z/d/drug information/16102.html" rel="external">
          vilazodone
         </a>
         have not been described, we taper drug doses of 20 to 40 mg per day for one to two weeks prior to discontinuation [
         <a href="#rid30">
          30
         </a>
         ]; tapering is the preferred method of discontinuing any psychotropic medication. Additional information about discontinuing antidepressants is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/105323.html" rel="external">
          "Discontinuing antidepressant medications in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H664513">
         <span class="h2">
          Side effects
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="16102" href="/z/d/drug information/16102.html" rel="external">
          Vilazodone
         </a>
         can cause several side effects  (
         <a class="graphic graphic_table graphicRef62488" href="/z/d/graphic/62488.html" rel="external">
          table 3
         </a>
         ). A pooled analysis examined adverse effects in two randomized trials that compared vilazodone 40 mg per day with placebo for eight weeks in 891 patients with unipolar major depression; the following adverse effects occurred more often in patients who received vilazodone than placebo, and the incidence with vilazodone was as follows [
         <a href="#rid33">
          33
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Diarrhea – 28 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Nausea – 23 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Sexual dysfunction – 16 percent of males and 5 percent of females
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Dizziness – 8 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Insomnia – 6 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Vomiting – 5 percent
        </p>
        <p>
        </p>
        <p>
         Although discontinuation of treatment due to side effects was greater in patients who received
         <a class="drug drug_general" data-topicid="16102" href="/z/d/drug information/16102.html" rel="external">
          vilazodone
         </a>
         than placebo (7 versus 3 percent) [
         <a href="#rid33">
          33
         </a>
         ], the clinical effect was small. A pooled analysis of two randomized trials lasting eight weeks (n = 891) compared vilazodone (40 mg/day) to placebo with regard to discontinuation of treatment due to adverse effects [
         <a href="#rid34">
          34
         </a>
         ]. The analysis found that the number needed to harm was 27; this means that on average, a clinician would need to treat 27 patients with vilazodone and 27 patients with placebo before observing one more patient stopping vilazodone than placebo because of an adverse event.
        </p>
        <p>
         Patients treated with
         <a class="drug drug_general" data-topicid="16102" href="/z/d/drug information/16102.html" rel="external">
          vilazodone
         </a>
         have reported the potentially life threatening serotonin syndrome. In premarketing studies of patients with unipolar major depression, symptoms of the syndrome were found in 0.1 percent [
         <a href="#rid35">
          35
         </a>
         ]. The clinical features and management of the serotonin syndrome are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/301.html" rel="external">
          "Serotonin syndrome (serotonin toxicity)"
         </a>
         .)
        </p>
        <p>
         Concerns have been raised about the possibility that maternal use of
         <a class="drug drug_general" data-topicid="16102" href="/z/d/drug information/16102.html" rel="external">
          vilazodone
         </a>
         during pregnancy may cause persistent pulmonary hypertension of the newborn. (See
         <a class="medical medical_review" href="/z/d/html/5007.html" rel="external">
          "Antenatal exposure to selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs): Neonatal outcomes", section on 'Persistent pulmonary hypertension of the newborn'
         </a>
         .)
        </p>
        <p>
         Based upon placebo controlled trials,
         <a class="drug drug_general" data-topicid="16102" href="/z/d/drug information/16102.html" rel="external">
          vilazodone
         </a>
         appears to have little or no effect upon [
         <a href="#rid32">
          32,33
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Vital signs
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Electrocardiogram parameters (including cardiac repolarization [corrected QT interval])
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Laboratory tests (including liver function tests)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Body weight
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H664520">
         <span class="h2">
          Overdose
         </span>
         <span class="headingEndMark">
          —
         </span>
         The clinical features, toxicology, and management of overdoses with
         <a class="drug drug_general" data-topicid="16102" href="/z/d/drug information/16102.html" rel="external">
          vilazodone
         </a>
         are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/15239.html" rel="external">
          "Acute poisoning from atypical (non-SSRI) antidepressants, including serotonin modulators and serotonin-norepinephrine reuptake inhibitors (SNRIs)"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1550268052">
         <span class="h1">
          VORTIOXETINE
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="91014" href="/z/d/drug information/91014.html" rel="external">
          Vortioxetine
         </a>
         is used to treat major depression [
         <a href="#rid36">
          36-38
         </a>
         ]. In addition, improvement of cognitive dysfunction in patients with unipolar major depression may be greater with vortioxetine than other antidepressants (eg,
         <a class="drug drug_general" data-topicid="8484" href="/z/d/drug information/8484.html" rel="external">
          duloxetine
         </a>
         ), and this benefit may be independent of resolving the depressive syndrome [
         <a href="#rid39">
          39,40
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1444185189">
         <span class="h2">
          Pharmacology
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="91014" href="/z/d/drug information/91014.html" rel="external">
          Vortioxetine
         </a>
         is a bis-aryl-sulphanyl amine that inhibits presynaptic reuptake of serotonin, which is considered the primary mechanism of action underlying the drug’s antidepressant effect [
         <a href="#rid41">
          41
         </a>
         ]. In addition, vortioxetine interacts with several serotonin receptor subtypes; the medication is a potent antagonist at serotonin 5-HT3 receptors, a weaker antagonist at 5-HT7 and 5-HT1D receptors, a partial agonist at 5-HT1B receptors, and a full agonist at 5-HT1A receptors [
         <a href="#rid42">
          42-44
         </a>
         ]. The downstream pharmacodynamic effects include increased levels of serotonin, acetylcholine, dopamine, and norepinephrine in specific areas of the brain [
         <a href="#rid45">
          45
         </a>
         ]. Although the clinical significance of the drug’s effects upon the serotonin receptor subtypes is unknown [
         <a href="#rid41">
          41,43
         </a>
         ], these effects may perhaps mediate the drug’s therapeutic benefits and its side effect profile [
         <a href="#rid40">
          40,43
         </a>
         ].
        </p>
        <p>
         The pharmacokinetic parameters of
         <a class="drug drug_general" data-topicid="91014" href="/z/d/drug information/91014.html" rel="external">
          vortioxetine
         </a>
         are displayed in the table  (
         <a class="graphic graphic_table graphicRef88062" href="/z/d/graphic/88062.html" rel="external">
          table 6
         </a>
         ) [
         <a href="#rid41">
          41,46
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2142845701">
         <span class="h2">
          Administration, dose, and discontinuation
         </span>
         <span class="headingEndMark">
          —
         </span>
         We suggest starting
         <a class="drug drug_general" data-topicid="91014" href="/z/d/drug information/91014.html" rel="external">
          vortioxetine
         </a>
         at a dose of 10 mg once daily  (
         <a class="graphic graphic_table graphicRef53818" href="/z/d/graphic/53818.html" rel="external">
          table 5
         </a>
         ) [
         <a href="#rid41">
          41
         </a>
         ]. For patients who tolerate the drug in week 1, the dose is increased to the target dose of 20 mg per day. However, a reasonable alternative is to initiate treatment with a dose of 5 mg/day for week 1 and then titrate up to 10 mg/day for week 2, followed by either 20 mg/day for week 3 or 15 mg/day for week 3 and 20 mg/day for week 4. In addition, it is reasonable to evaluate the effectiveness of each dose for two to four weeks before titrating up. (Multiple randomized trials found that vortioxetine 5, 10, 15, and 20 mg/day were each superior to placebo [
         <a href="#rid37">
          37,47
         </a>
         ]).
        </p>
        <p>
         Dose adjustments are not required for older patients (eg, age ≥65 years) and for patients with renal impairment or mild to moderate hepatic impairment; use of the drug in patients with severe hepatic impairment has not been studied [
         <a href="#rid41">
          41,43
         </a>
         ].
        </p>
        <p>
         <a class="drug drug_general" data-topicid="91014" href="/z/d/drug information/91014.html" rel="external">
          Vortioxetine
         </a>
         undergoes extensive metabolism by hepatic cytochrome P450 2D6 (CYP2D6) enzymes and is also metabolized by other CYP enzymes [
         <a href="#rid4">
          4
         </a>
         ]. For patients who slowly metabolize CYP2D6 substrates, the maximum recommended dose is 10 mg/day. In addition, dose adjustments may be necessary if vortioxetine is coadministered with medications that inhibit CYP2D6 metabolism  (
         <a class="graphic graphic_table graphicRef116164" href="/z/d/graphic/116164.html" rel="external">
          table 2
         </a>
         ), or medications that induce other CYP metabolic pathways (eg,
         <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">
          carbamazepine
         </a>
         and
         <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">
          phenytoin
         </a>
         ). Thus, prior to initiating or altering therapy with vortioxetine, clinicians should check drug-drug interactions with other medications using the
         <a class="external" href="/drug-interactions">
          drug interactions program
         </a>
         included in UpToDate. The
         <a class="external" href="/drug-interactions">
          drug interaction tool
         </a>
         provides specific dose recommendations for administering vortioxetine concomitantly with strong CYP2D6 inhibitors or with inducers of other CYP enzymes.
        </p>
        <p>
         Although abrupt discontinuation of
         <a class="drug drug_general" data-topicid="91014" href="/z/d/drug information/91014.html" rel="external">
          vortioxetine
         </a>
         does not cause a withdrawal syndrome, we taper drug doses of 15 or 20 mg/day to 10 mg/day for one week before stopping it [
         <a href="#rid41">
          41,46
         </a>
         ]; tapering is the preferred method of discontinuing any psychotropic medication. Evidence regarding the lack of discontinuation symptoms includes the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Three randomized trials lasting eight weeks compared
         <a class="drug drug_general" data-topicid="91014" href="/z/d/drug information/91014.html" rel="external">
          vortioxetine
         </a>
         (10, 15, or 20 mg/day) with placebo in patients with acute unipolar major depression (n &gt;1300), and then abruptly stopped the study drugs [
         <a href="#rid48">
          48
         </a>
         ]. During the subsequent two weeks, the level of withdrawal symptoms was comparable for the two groups, which was probably due to the relatively long half-life of vortioxetine  (
         <a class="graphic graphic_table graphicRef88062" href="/z/d/graphic/88062.html" rel="external">
          table 6
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A maintenance treatment study (n = 396 remitted patients) compared
         <a class="drug drug_general" data-topicid="91014" href="/z/d/drug information/91014.html" rel="external">
          vortioxetine
         </a>
         (5 or 10 mg/day) with placebo for up to 64 weeks and then abruptly stopped the study drugs [
         <a href="#rid49">
          49
         </a>
         ]. During the subsequent two weeks, the level of withdrawal symptoms was comparable for the two groups.
        </p>
        <p>
        </p>
        <p>
         Additional information about discontinuing antidepressants is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/105323.html" rel="external">
          "Discontinuing antidepressant medications in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3888814663">
         <span class="h2">
          Side effects
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although
         <a class="drug drug_general" data-topicid="91014" href="/z/d/drug information/91014.html" rel="external">
          vortioxetine
         </a>
         can cause several side effects, especially nausea  (
         <a class="graphic graphic_table graphicRef62488" href="/z/d/graphic/62488.html" rel="external">
          table 3
         </a>
         ), the drug is generally well tolerated [
         <a href="#rid43">
          43,48
         </a>
         ]. As an example, a pooled analysis of 11 short-term (six or eight weeks) randomized trials compared vortioxetine (5 to 20 mg/day) with placebo in patients with unipolar major depression (n &gt;4800) [
         <a href="#rid34">
          34
         </a>
         ]. The analysis found that the number needed to harm, defined as discontinuing treatment due to side effects, was 43. This means that on average, a clinician would need to treat 43 patients with vortioxetine and 43 patients with placebo before observing one more patient stopping vortioxetine than placebo because of an adverse event. Nevertheless, randomized trials have demonstrated that the overall difference between vortioxetine and placebo, with regard to stopping treatment due to adverse effects, is statistically significant [
         <a href="#rid36">
          36,50
         </a>
         ].
        </p>
        <p>
         Based upon a pooled analysis of 11 short-term randomized trials that compared
         <a class="drug drug_general" data-topicid="91014" href="/z/d/drug information/91014.html" rel="external">
          vortioxetine
         </a>
         with placebo in depressed patients (n &gt;4800), the absolute rate of discontinuing treatment due to adverse effects was as follows [
         <a href="#rid48">
          48
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Placebo – 4 percent of patients
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="91014" href="/z/d/drug information/91014.html" rel="external">
          Vortioxetine
         </a>
         5 mg/day – 5 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="91014" href="/z/d/drug information/91014.html" rel="external">
          Vortioxetine
         </a>
         10 mg/day – 5 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="91014" href="/z/d/drug information/91014.html" rel="external">
          Vortioxetine
         </a>
         15 mg/day – 8 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="91014" href="/z/d/drug information/91014.html" rel="external">
          Vortioxetine
         </a>
         20 mg/day – 7 percent
        </p>
        <p>
        </p>
        <p>
         Comparable figures are found in longer studies. A maintenance trial included 396 patients who initially remitted with open-label
         <a class="drug drug_general" data-topicid="91014" href="/z/d/drug information/91014.html" rel="external">
          vortioxetine
         </a>
         and were then randomly assigned to vortioxetine (5 or 10 mg/day) or placebo for treatment lasting up to 64 weeks [
         <a href="#rid49">
          49
         </a>
         ]. Discontinuation of treatment due to adverse events occurred in 8 and 3 percent of patients.
        </p>
        <p>
         The side effect that most often causes patients to stop
         <a class="drug drug_general" data-topicid="91014" href="/z/d/drug information/91014.html" rel="external">
          vortioxetine
         </a>
         is nausea [
         <a href="#rid48">
          48
         </a>
         ], and the most frequent side effect of vortioxetine is nausea [
         <a href="#rid43">
          43
         </a>
         ]. A pooled analysis of 11 short-term randomized trials (n &gt;4800 depressed patients) compared vortioxetine with placebo and found that the incidence of nausea was as follows [
         <a href="#rid48">
          48
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Placebo – 8 percent of patients
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="91014" href="/z/d/drug information/91014.html" rel="external">
          Vortioxetine
         </a>
         5 mg/day – 21 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="91014" href="/z/d/drug information/91014.html" rel="external">
          Vortioxetine
         </a>
         10 mg/day – 23 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="91014" href="/z/d/drug information/91014.html" rel="external">
          Vortioxetine
         </a>
         15 mg/day – 31 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="91014" href="/z/d/drug information/91014.html" rel="external">
          Vortioxetine
         </a>
         20 mg/day – 28 percent
        </p>
        <p>
        </p>
        <p>
         Onset of nausea was most frequent in week 1 [
         <a href="#rid41">
          41
         </a>
         ], and the median duration of nausea was 9 to 16 days, depending upon the dose [
         <a href="#rid48">
          48
         </a>
         ]. Among patients taking 10 to 20 mg/day at the end of the short-term trials, nausea was present in 10 percent [
         <a href="#rid41">
          41
         </a>
         ].
        </p>
        <p>
         In addition, a study treated acutely depressed patients with open-label
         <a class="drug drug_general" data-topicid="91014" href="/z/d/drug information/91014.html" rel="external">
          vortioxetine
         </a>
         for 12 weeks and then randomly assigned remitted patients (n = 396) to vortioxetine (5 or 10 mg/day) or placebo for maintenance treatment lasting up to 64 weeks; the incidence of nausea was greater with vortioxetine than placebo (9 versus 3 percent of patients) [
         <a href="#rid49">
          49
         </a>
         ].
        </p>
        <p>
         Other side effects that occur more often with
         <a class="drug drug_general" data-topicid="91014" href="/z/d/drug information/91014.html" rel="external">
          vortioxetine
         </a>
         than placebo include vomiting and constipation [
         <a href="#rid51">
          51
         </a>
         ]. However, the incidence of vomiting and constipation is relatively low, compared with the incidence of nausea. As an example, a pooled analysis of 11 short-term randomized trials (n &gt;4800 depressed patients) found that the frequency of vomiting in patients treated with vortioxetine (5 to 20 mg/day) ranged from 3 to 6 percent, depending upon the dose; the rate with placebo was 1 percent [
         <a href="#rid48">
          48
         </a>
         ]. Similarly, the frequency of constipation in patients treated with vortioxetine ranged from 3 to 6 percent, and the rate with placebo was 3 percent.
        </p>
        <p>
         In multiple short-term randomized trials of acutely depressed patients,
         <a class="drug drug_general" data-topicid="91014" href="/z/d/drug information/91014.html" rel="external">
          vortioxetine
         </a>
         and placebo were comparable with regard to changes in electrocardiogram parameters, laboratory values (eg, complete blood counts, electrolytes, and liver function tests), and vital signs [
         <a href="#rid48">
          48
         </a>
         ]. Similar results were found in one randomized trial that compared vortioxetine (5 or 10 mg/day) with placebo as maintenance treatment in patients (n = 396) [
         <a href="#rid49">
          49
         </a>
         ]. In addition, patients who initially completed five short-term randomized trials (total n = 2587) were treated with vortioxetine in open-label extension studies; no clinically significant changes in electrocardiogram parameters, laboratory values, or vital signs were observed [
         <a href="#rid52">
          52-56
         </a>
         ].
        </p>
        <p>
         Other studies suggest that side effects are less problematic with
         <a class="drug drug_general" data-topicid="91014" href="/z/d/drug information/91014.html" rel="external">
          vortioxetine
         </a>
         than other antidepressants, such as agomelatine,
         <a class="drug drug_general" data-topicid="8484" href="/z/d/drug information/8484.html" rel="external">
          duloxetine
         </a>
         , and
         <a class="drug drug_general" data-topicid="10042" href="/z/d/drug information/10042.html" rel="external">
          venlafaxine
         </a>
         [
         <a href="#rid57">
          57,58
         </a>
         ]. As an example, a meta-analysis of five randomized trials (n &gt;2000 depressed patients) lasting eight weeks compared vortioxetine (2.5 to 20 mg/day) with duloxetine (60 mg/day) and found that adverse effects were less likely to occur with vortioxetine than duloxetine (relative risk 0.88, 95% CI 0.82-0.94), including nausea (relative risk 0.70, 95% CI 0.56-0.87) [
         <a href="#rid59">
          59
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1253710407">
         <span class="h2">
          Overdose
         </span>
         <span class="headingEndMark">
          —
         </span>
         The clinical features, toxicology, and management of overdoses with
         <a class="drug drug_general" data-topicid="16102" href="/z/d/drug information/16102.html" rel="external">
          vilazodone
         </a>
         are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/15239.html" rel="external">
          "Acute poisoning from atypical (non-SSRI) antidepressants, including serotonin modulators and serotonin-norepinephrine reuptake inhibitors (SNRIs)"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H664527">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, “The Basics” and “Beyond the Basics.” The Basics patient education pieces are written in plain language, at the 5th to 6th grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10th to 12th grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on “patient info” and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topics (see
         <a class="medical medical_basics" href="/z/d/html/16338.html" rel="external">
          "Patient education: Coping with high drug prices (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topics (see
         <a class="medical medical_patient" href="/z/d/html/4866.html" rel="external">
          "Patient education: Depression treatment options for adults (Beyond the Basics)"
         </a>
         and
         <a class="medical medical_patient" href="/z/d/html/4868.html" rel="external">
          "Patient education: Depression in adults (Beyond the Basics)"
         </a>
         and
         <a class="medical medical_patient" href="/z/d/html/16279.html" rel="external">
          "Patient education: Coping with high prescription drug prices in the United States (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p>
         The National Institute of Mental Health also has educational material on the use of antidepressants, including SSRIs, entitled, "What medications are used to treat depression?" that is available online at
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.nimh.nih.gov%2Fhealth%2Ftopics%2Fmental-health-medications&amp;token=DUyqmXMqVzfwMQwHS0hGhjVnvSmWNYwrVIOQjil9H1c7QeKzCSx0qXlroHThkaY5AZSlsPjqMvW2SrhzIcY0ie182z2bJyFkd3seZ7M6%2Fa0%3D&amp;TOPIC_ID=86265" target="_blank">
          the website
         </a>
         . Material explaining the symptoms, causes, and treatment for depression is also available in a booklet entitled "Depression" that is available online at
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.nimh.nih.gov%2Fhealth%2Fpublications%2Fdepression&amp;token=lblfowwGB6QwC91WNuiIf4ajjCUnrtrjbsV3PkfR7znk0D5d%2Fr0ErMPgiqIitkwYLP%2FHA1tFvsLfSIGbbHxrmA%3D%3D&amp;TOPIC_ID=86265" target="_blank">
          the website
         </a>
         . Both publications can also be obtained through a toll-free number, 866-615-6464. The web site also provides references, summaries of study results in language intended for the lay public, and information about clinical trials currently recruiting patients.
        </p>
        <p>
         The Depression and Bipolar Support Alliance (available at
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.dbsalliance.org%2F&amp;token=ZAuWdG5s4GIvjFnkWRP6rC6dBWU8%2FMZEcwGeeAm5c58EpMgcvhu2s4%2FQc68YQejm&amp;TOPIC_ID=86265" target="_blank">
          the website
         </a>
         or 800-826-3632) is a national organization whose mission is to educate members about depression and how to cope with it. Other functions include increasing public awareness of the illness and advocating for more research and services. The organization is administered and maintained by patients and family members, and has local chapters.
        </p>
        <p>
         The National Alliance on Mental Illness (available at
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.nami.org%2FHome&amp;token=wEsKVFvqlKzpT%2BqOtddW%2F8kABYN690CzsdrTBuRq2QekIBbQQeqX70Vmx%2B0z8d0m&amp;TOPIC_ID=86265" target="_blank">
          the website
         </a>
         or 800-950-6264) is a similarly structured organization devoted to providing education, support, and advocacy for patients with any mental illness. Depression is one of their priorities.
        </p>
        <p class="headingAnchor" id="H664534">
         <span class="h1">
          SUMMARY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Specific drugs
         </strong>
         – Serotonin modulators include
         <a class="drug drug_general" data-topicid="9684" href="/z/d/drug information/9684.html" rel="external">
          nefazodone
         </a>
         ,
         <a class="drug drug_general" data-topicid="10013" href="/z/d/drug information/10013.html" rel="external">
          trazodone
         </a>
         ,
         <a class="drug drug_general" data-topicid="16102" href="/z/d/drug information/16102.html" rel="external">
          vilazodone
         </a>
         , and
         <a class="drug drug_general" data-topicid="91014" href="/z/d/drug information/91014.html" rel="external">
          vortioxetine
         </a>
         . (See
         <a class="local">
          'Introduction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pharmacokinetics
         </strong>
         – The pharmacokinetic parameters of serotonin modulators are presented in the table  (
         <a class="graphic graphic_table graphicRef88062" href="/z/d/graphic/88062.html" rel="external">
          table 6
         </a>
         ).
         <a class="drug drug_general" data-topicid="9684" href="/z/d/drug information/9684.html" rel="external">
          Nefazodone
         </a>
         may inhibit the hepatic enzyme CYP3A4. (See
         <a class="local">
          'Drug interactions and metabolism'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          What to discuss with patients
         </strong>
         – Prior to prescribing serotonin modulators, clinicians should discuss drug interactions, side effects  (
         <a class="graphic graphic_table graphicRef62488" href="/z/d/graphic/62488.html" rel="external">
          table 3
         </a>
         ), time to response, and stopping the medication.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Medical tests and plasma levels
         </strong>
         – No specific medical tests are required before starting serotonin modulators, and drug plasma levels are not routinely performed. (See
         <a class="local">
          'General principles'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dosing
         </strong>
         – We suggest starting with a low dose in order to avoid side effects  (
         <a class="graphic graphic_table graphicRef62488" href="/z/d/graphic/62488.html" rel="external">
          table 3
         </a>
         ) and slowly increasing the dose. Starting doses and target dose ranges of each serotonin modulator are listed in the table  (
         <a class="graphic graphic_table graphicRef53818" href="/z/d/graphic/53818.html" rel="external">
          table 5
         </a>
         ). (See
         <a class="local">
          'Dosing'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adverse effects
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Serotonin syndrome
         </strong>
         – Serotonin modulators can cause the serotonin syndrome. (See
         <a class="medical medical_review" href="/z/d/html/301.html" rel="external">
          "Serotonin syndrome (serotonin toxicity)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Nefazodone
         </strong>
         –
         <a class="drug drug_general" data-topicid="9684" href="/z/d/drug information/9684.html" rel="external">
          Nefazodone
         </a>
         can injure the liver and is contraindicated in patients with elevated serum transaminases, active liver disease, or liver injury due to previous nefazodone treatment. Other adverse effects include nausea, somnolence, dry mouth, dizziness, constipation, weakness, and blurred vision. (See
         <a class="local">
          'Nefazodone'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Trazodone
         </strong>
         – Common adverse effects of
         <a class="drug drug_general" data-topicid="10013" href="/z/d/drug information/10013.html" rel="external">
          trazodone
         </a>
         include somnolence, dry mouth, dizziness, fatigue, constipation, vision blurred, sexual dysfunction, orthostatic hypotension, and headache. Rare but serious side effects include priapism and cardiac arrhythmias. (See
         <a class="local">
          'Trazodone'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Vilazodone
         </strong>
         – Adverse effects of
         <a class="drug drug_general" data-topicid="16102" href="/z/d/drug information/16102.html" rel="external">
          vilazodone
         </a>
         include diarrhea, nausea, sexual dysfunction, dizziness, insomnia, and vomiting. (See
         <a class="local">
          'Vilazodone'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Vortioxetine
         </strong>
         – The primary adverse effect of
         <a class="drug drug_general" data-topicid="91014" href="/z/d/drug information/91014.html" rel="external">
          vortioxetine
         </a>
         is nausea. Other potential side effects include vomiting and constipation. (See
         <a class="local">
          'Vortioxetine'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Horst WD, Preskorn SH. Mechanisms of action and clinical characteristics of three atypical antidepressants: venlafaxine, nefazodone, bupropion. J Affect Disord 1998; 51:237.
          </a>
         </li>
         <li class="breakAll">
          Viibryd (vilazodone hydrochloride) US prescribing information (revised January 2020) https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022567s021lbl.pdf (Accessed on April 11, 2020).
         </li>
         <li class="breakAll">
          Trazodone US prescribing information (December 2018) https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?setid=b48c8d16-ad28-47f2-9a85-4ef97bdd4bfc&amp;type=pdf (Accessed on April 11, 2020).
         </li>
         <li class="breakAll">
          Trintellix (vortioxetine tablets) US prescribing information (revised July 2019) https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/204447s018lbl.pdf (Accessed on April 11, 2020).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Greene DS, Barbhaiya RH. Clinical pharmacokinetics of nefazodone. Clin Pharmacokinet 1997; 33:260.
          </a>
         </li>
         <li class="breakAll">
          Nefazodone US prescribing information (September 2015) https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?setid=51ff7db5-aaf9-4c3c-86e6-958ebf16b60f&amp;type=pdf (Accessed on April 11, 2020).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nierenberg AA, Fava M, Trivedi MH, et al. A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report. Am J Psychiatry 2006; 163:1519.
          </a>
         </li>
         <li class="breakAll">
          Golden RN, Dawkins K, Nicholas L. Trazodone and nefazodone. In: The American Psychiatric Publishing Textbook of Psychopharmacology, Fourth Edition, Schatzberg AF, Nemeroff CB (Eds), American Psychiatric Publishing, Inc., Washington, D.C. 2009. p.403.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Davis R, Whittington R, Bryson HM. Nefazodone. A review of its pharmacology and clinical efficacy in the management of major depression. Drugs 1997; 53:608.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           DeVane CL, Grothe DR, Smith SL. Pharmacology of antidepressants: focus on nefazodone. J Clin Psychiatry 2002; 63 Suppl 1:10.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zajecka J, McEnany GW, Lusk KM. Antidepressant dosing and switching guidelines: focus on nefazodone. J Clin Psychiatry 2002; 63 Suppl 1:42.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dunner DL, Laird LK, Zajecka J, et al. Six-year perspectives on the safety and tolerability of nefazodone. J Clin Psychiatry 2002; 63 Suppl 1:32.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Feiger AD, Bielski RJ, Bremner J, et al. Double-blind, placebo-substitution study of nefazodone in the prevention of relapse during continuation treatment of outpatients with major depression. Int Clin Psychopharmacol 1999; 14:19.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carvajal García-Pando A, García del Pozo J, Sánchez AS, et al. Hepatotoxicity associated with the new antidepressants. J Clin Psychiatry 2002; 63:135.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stewart DE. Hepatic adverse reactions associated with nefazodone. Can J Psychiatry 2002; 47:375.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spigset O, Hägg S, Bate A. Hepatic injury and pancreatitis during treatment with serotonin reuptake inhibitors: data from the World Health Organization (WHO) database of adverse drug reactions. Int Clin Psychopharmacol 2003; 18:157.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Suzuki A, Andrade RJ, Bjornsson E, et al. Drugs associated with hepatotoxicity and their reporting frequency of liver adverse events in VigiBase: unified list based on international collaborative work. Drug Saf 2010; 33:503.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Robinson DS, Roberts DL, Smith JM, et al. The safety profile of nefazodone. J Clin Psychiatry 1996; 57 Suppl 2:31.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Serretti A, Chiesa A. Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis. J Clin Psychopharmacol 2009; 29:259.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sussman N, Ginsberg DL, Bikoff J. Effects of nefazodone on body weight: a pooled analysis of selective serotonin reuptake inhibitor- and imipramine-controlled trials. J Clin Psychiatry 2001; 62:256.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nierenberg AA, Adler LA, Peselow E, et al. Trazodone for antidepressant-associated insomnia. Am J Psychiatry 1994; 151:1069.
          </a>
         </li>
         <li class="breakAll">
          DrugBank http://www.drugbank.ca/ (Accessed on July 29, 2012).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sheehan DV, Croft HA, Gossen ER, et al. Extended-release Trazodone in Major Depressive Disorder: A Randomized, Double-blind, Placebo-controlled Study. Psychiatry (Edgmont) 2009; 6:20.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mendelson WB. A review of the evidence for the efficacy and safety of trazodone in insomnia. J Clin Psychiatry 2005; 66:469.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haria M, Fitton A, McTavish D. Trazodone. A review of its pharmacology, therapeutic use in depression and therapeutic potential in other disorders. Drugs Aging 1994; 4:331.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cunningham LA, Borison RL, Carman JS, et al. A comparison of venlafaxine, trazodone, and placebo in major depression. J Clin Psychopharmacol 1994; 14:99.
          </a>
         </li>
         <li class="breakAll">
          Labbate LA, Fava M, Rosenbaum JF, Arana GW. Drugs for the treatment of depression. In: Handbook of Psychiatric Drug Therapy, Sixth Edition, Lippincott Williams &amp; Wilkins, Philadelphia 2010. p.54.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thompson JW Jr, Ware MR, Blashfield RK. Psychotropic medication and priapism: a comprehensive review. J Clin Psychiatry 1990; 51:430.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Serretti A, Mandelli L. Antidepressants and body weight: a comprehensive review and meta-analysis. J Clin Psychiatry 2010; 71:1259.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McCormack PL. Vilazodone: a review in major depressive disorder in adults. Drugs 2015; 75:1915.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rickels K, Athanasiou M, Robinson DS, et al. Evidence for efficacy and tolerability of vilazodone in the treatment of major depressive disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2009; 70:326.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Frampton JE. Vilazodone: in major depressive disorder. CNS Drugs 2011; 25:615.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Citrome L. Vilazodone for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract 2012; 66:356.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Citrome L. Vortioxetine for major depressive disorder: An indirect comparison with duloxetine, escitalopram, levomilnacipran, sertraline, venlafaxine, and vilazodone, using number needed to treat, number needed to harm, and likelihood to be helped or harmed. J Affect Disord 2016; 196:225.
          </a>
         </li>
         <li class="breakAll">
          Vilazodone. US Food &amp; Drug Administration (FDA) approved product information. Revised April, 2014. US National Library of Medicine. (Available online at www.dailymed.nlm.nih.gov. www.dailymed.nlm.nih.gov (Accessed on April 15, 2014).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pae CU, Wang SM, Han C, et al. Vortioxetine: a meta-analysis of 12 short-term, randomized, placebo-controlled clinical trials for the treatment of major depressive disorder. J Psychiatry Neurosci 2015; 40:174.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thase ME, Mahableshwarkar AR, Dragheim M, et al. A meta-analysis of randomized, placebo-controlled trials of vortioxetine for the treatment of major depressive disorder in adults. Eur Neuropsychopharmacol 2016; 26:979.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baldwin DS, Florea I, Jacobsen PL, et al. A meta-analysis of the efficacy of vortioxetine in patients with major depressive disorder (MDD) and high levels of anxiety symptoms. J Affect Disord 2016; 206:140.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McIntyre RS, Harrison J, Loft H, et al. The Effects of Vortioxetine on Cognitive Function in Patients with Major Depressive Disorder: A Meta-Analysis of Three Randomized Controlled Trials. Int J Neuropsychopharmacol 2016.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thase ME. US Food and Drug Administration's review of the novel antidepressant vortioxetine. J Clin Psychiatry 2015; 76:e120.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhang J, Mathis MV, Sellers JW, et al. The US Food and Drug Administration's perspective on the new antidepressant vortioxetine. J Clin Psychiatry 2015; 76:8.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bang-Andersen B, Ruhland T, Jørgensen M, et al. Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder. J Med Chem 2011; 54:3206.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kelliny M, Croarkin PE, Moore KM, Bobo WV. Profile of vortioxetine in the treatment of major depressive disorder: an overview of the primary and secondary literature. Ther Clin Risk Manag 2015; 11:1193.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mørk A, Pehrson A, Brennum LT, et al. Pharmacological effects of Lu AA21004: a novel multimodal compound for the treatment of major depressive disorder. J Pharmacol Exp Ther 2012; 340:666.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sanchez C, Asin KE, Artigas F. Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data. Pharmacol Ther 2015; 145:43.
          </a>
         </li>
         <li class="breakAll">
          Trintellix (vortioxetine), package insert. Deerfield, IL; Lundbeck; 2016 https://us.trintellix.com (Accessed on May 10, 2017).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Citrome L. Vortioxetine for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract 2014; 68:60.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baldwin DS, Chrones L, Florea I, et al. The safety and tolerability of vortioxetine: Analysis of data from randomized placebo-controlled trials and open-label extension studies. J Psychopharmacol 2016; 30:242.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boulenger JP, Loft H, Florea I. A randomized clinical study of Lu AA21004 in the prevention of relapse in patients with major depressive disorder. J Psychopharmacol 2012; 26:1408.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meeker AS, Herink MC, Haxby DG, Hartung DM. The safety and efficacy of vortioxetine for acute treatment of major depressive disorder: a systematic review and meta-analysis. Syst Rev 2015; 4:21.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li G, Wang X, Ma D. The efficacy and safety of 10 mg vortioxetine in the treatment of major depressive disorder: a meta-analysis of randomized controlled trials. Neuropsychiatr Dis Treat 2016; 12:523.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baldwin DS, Hansen T, Florea I. Vortioxetine (Lu AA21004) in the long-term open-label treatment of major depressive disorder. Curr Med Res Opin 2012; 28:1717.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alam MY, Jacobsen PL, Chen Y, et al. Safety, tolerability, and efficacy of vortioxetine (Lu AA21004) in major depressive disorder: results of an open-label, flexible-dose, 52-week extension study. Int Clin Psychopharmacol 2014; 29:36.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jacobsen PL, Harper L, Chrones L, et al. Safety and tolerability of vortioxetine (15 and 20 mg) in patients with major depressive disorder: results of an open-label, flexible-dose, 52-week extension study. Int Clin Psychopharmacol 2015; 30:255.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Filippov G, Christens P. Vortioxetine (Lu AA21004 15 and 20 mg/day: open-label long-term safety and tolerability in major depressive disorder). Eur Neuropsychopharmacol 2013; 23 (Suppl. 2):S325.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Florea I, Dragheim M, Loft H. The multimodal antidepressant Lu AA21004: open-label long-term safety and tolderability study in major depressive disorder. Eur Neuropsychopharmacol 2012; 22 (Suppl. 2):S255.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Montgomery SA, Nielsen RZ, Poulsen LH, Häggström L. A randomised, double-blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin-noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelatine. Hum Psychopharmacol 2014; 29:470.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alvarez E, Perez V, Dragheim M, et al. A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder. Int J Neuropsychopharmacol 2012; 15:589.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li G, Wang X, Ma D. Vortioxetine versus Duloxetine in the Treatment of Patients with Major Depressive Disorder: A Meta-Analysis of Randomized Controlled Trials. Clin Drug Investig 2016; 36:509.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 86265 Version 25.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10333980" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Mechanisms of action and clinical characteristics of three atypical antidepressants: venlafaxine, nefazodone, bupropion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10333980" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Mechanisms of action and clinical characteristics of three atypical antidepressants: venlafaxine, nefazodone, bupropion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10333980" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Mechanisms of action and clinical characteristics of three atypical antidepressants: venlafaxine, nefazodone, bupropion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10333980" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Mechanisms of action and clinical characteristics of three atypical antidepressants: venlafaxine, nefazodone, bupropion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9342502" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Clinical pharmacokinetics of nefazodone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9342502" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Clinical pharmacokinetics of nefazodone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16946176" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16946176" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9098663" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Nefazodone. A review of its pharmacology and clinical efficacy in the management of major depression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11890560" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Pharmacology of antidepressants: focus on nefazodone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11890564" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Antidepressant dosing and switching guidelines: focus on nefazodone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11890563" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Six-year perspectives on the safety and tolerability of nefazodone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10221638" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Double-blind, placebo-substitution study of nefazodone in the prevention of relapse during continuation treatment of outpatients with major depression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11874214" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Hepatotoxicity associated with the new antidepressants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12025437" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Hepatic adverse reactions associated with nefazodone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12702895" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Hepatic injury and pancreatitis during treatment with serotonin reuptake inhibitors: data from the World Health Organization (WHO) database of adverse drug reactions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20486732" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Drugs associated with hepatotoxicity and their reporting frequency of liver adverse events in VigiBase: unified list based on international collaborative work.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8626361" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : The safety profile of nefazodone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19440080" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11379839" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Effects of nefazodone on body weight: a pooled analysis of selective serotonin reuptake inhibitor- and imipramine-controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8010365" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Trazodone for antidepressant-associated insomnia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8010365" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Trazodone for antidepressant-associated insomnia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19724732" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Extended-release Trazodone in Major Depressive Disorder: A Randomized, Double-blind, Placebo-controlled Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15816789" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : A review of the evidence for the efficacy and safety of trazodone in insomnia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8019056" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Trazodone. A review of its pharmacology, therapeutic use in depression and therapeutic potential in other disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8195464" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : A comparison of venlafaxine, trazodone, and placebo in major depression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8195464" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : A comparison of venlafaxine, trazodone, and placebo in major depression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2211542" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Psychotropic medication and priapism: a comprehensive review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21062615" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Antidepressants and body weight: a comprehensive review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26496736" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Vilazodone: a review in major depressive disorder in adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19284933" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Evidence for efficacy and tolerability of vilazodone in the treatment of major depressive disorder: a randomized, double-blind, placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21699273" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Vilazodone: in major depressive disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22284853" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Vilazodone for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26938965" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Vortioxetine for major depressive disorder: An indirect comparison with duloxetine, escitalopram, levomilnacipran, sertraline, venlafaxine, and vilazodone, using number needed to treat, number needed to harm, and likelihood to be helped or harmed.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26938965" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Vortioxetine for major depressive disorder: An indirect comparison with duloxetine, escitalopram, levomilnacipran, sertraline, venlafaxine, and vilazodone, using number needed to treat, number needed to harm, and likelihood to be helped or harmed.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25350320" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Vortioxetine: a meta-analysis of 12 short-term, randomized, placebo-controlled clinical trials for the treatment of major depressive disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27139079" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : A meta-analysis of randomized, placebo-controlled trials of vortioxetine for the treatment of major depressive disorder in adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27474960" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : A meta-analysis of the efficacy of vortioxetine in patients with major depressive disorder (MDD) and high levels of anxiety symptoms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27312740" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : The Effects of Vortioxetine on Cognitive Function in Patients with Major Depressive Disorder: A Meta-Analysis of Three Randomized Controlled Trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25650679" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : US Food and Drug Administration's review of the novel antidepressant vortioxetine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25562777" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : The US Food and Drug Administration's perspective on the new antidepressant vortioxetine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21486038" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26316764" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Profile of vortioxetine in the treatment of major depressive disorder: an overview of the primary and secondary literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22171087" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Pharmacological effects of Lu AA21004: a novel multimodal compound for the treatment of major depressive disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25016186" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25016186" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24165478" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Vortioxetine for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26864543" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : The safety and tolerability of vortioxetine: Analysis of data from randomized placebo-controlled trials and open-label extension studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22495621" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : A randomized clinical study of Lu AA21004 in the prevention of relapse in patients with major depressive disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25874839" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : The safety and efficacy of vortioxetine for acute treatment of major depressive disorder: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27013879" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : The efficacy and safety of 10 mg vortioxetine in the treatment of major depressive disorder: a meta-analysis of randomized controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22978748" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Vortioxetine (Lu AA21004) in the long-term open-label treatment of major depressive disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24169027" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Safety, tolerability, and efficacy of vortioxetine (Lu AA21004) in major depressive disorder: results of an open-label, flexible-dose, 52-week extension study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26020712" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Safety and tolerability of vortioxetine (15 and 20 mg) in patients with major depressive disorder: results of an open-label, flexible-dose, 52-week extension study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Vortioxetine (Lu AA21004 15 and 20 mg/day: open-label long-term safety and tolerability in major depressive disorder)
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : The multimodal antidepressant Lu AA21004: open-label long-term safety and tolderability study in major depressive disorder
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25087600" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : A randomised, double-blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin-noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelatine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21767441" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27067232" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Vortioxetine versus Duloxetine in the Treatment of Patients with Major Depressive Disorder: A Meta-Analysis of Randomized Controlled Trials.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
